The latest FDA viewpoint confirms a growing shift across the Pharma industry: Digital Health Technologies (DHTs) are no longer a supplementary component—they’re becoming foundational to how trials are designed and evaluated.
DHTs enable data collection where patients live and work, reflecting real-life conditions and broadening access to clinical trials for more diverse and representative populations. They allow for continuous, passive monitoring of granular real-world endpoints—capturing everything from tremors to sleep to vital signs. This makes it possible to:
